Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN DON FOLKERTH

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1215985197
CMS profile
10174
Location
BEAVERCREEK, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$209.13

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $209.13 14

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN DON FOLKERTH

NPI 1215985197 · CMS profile ID 10174

Allopathic & Osteopathic Physicians / Internal Medicine

BEAVERCREEK, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215985197?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN DON FOLKERTH, NPI 1215985197, CMS profile ID 10174. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215985197?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). STEVEN DON FOLKERTH, NPI 1215985197, CMS profile ID 10174. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215985197?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
STEVEN DON FOLKERTH, NPI 1215985197, CMS profile ID 10174, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1215985197?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $209.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $12.2304/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672411411 CMS
Novartis Pharmaceuticals Corporation $16.1804/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660184469 CMS
PFIZER INC. $21.8404/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672414807 CMS
GlaxoSmithKline, LLC. $16.2304/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670758207 CMS
AstraZeneca Pharmaceuticals LP $11.2503/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685912095 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.3203/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700384781 CMS
PFIZER INC. $11.1003/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672459700 CMS
AstraZeneca Pharmaceuticals LP $11.3303/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685825127 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.5302/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684726579 CMS
Amarin Pharma Inc. $15.5502/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699077641 CMS
Amgen Inc. $18.5202/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663075691 CMS
PFIZER INC. $14.6302/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672415411 CMS
AstraZeneca Pharmaceuticals LP $12.3502/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685601573 CMS
PFIZER INC. $11.0701/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672461767 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $209.13 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $8,820.08 1
PY2024 Principal investigator $75,861.80 1
PY2023 Principal investigator $369,654.75 14
PY2022 Recipient $202.26 1
PY2022 Principal investigator $2,132,299.27 89
PY2021 Principal investigator $5,447,139.77 65
PY2020 Principal investigator $527,432.45 9
PY2019 Principal investigator $510,064.93 30

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

65 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $70.00 12/31/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE 2B, 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR No dispute reported 06/30/2026 838143819
Principal investigator 1 Innocoll Incorporated $472,314.00 12/22/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594463
Principal investigator 1 Innocoll Incorporated $3,500.00 12/22/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594465
Principal investigator 1 Innocoll Incorporated $2,500.00 12/22/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594467
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,010.00 12/22/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMIZED DOUBLE-BLIND, DOUBLE-DUMMY, PROOF OF CONCEPT PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-951 VERSUS ONDANSETRON IN THE PROPHYLAXIS OF POSTOPERATIVE NAUSEA AND VOMITING IN HIGH-RISK SUBJECTS No dispute reported 06/30/2026 816789509
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,750.00 12/22/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMIZED DOUBLE-BLIND, DOUBLE-DUMMY, PROOF OF CONCEPT PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-951 VERSUS ONDANSETRON IN THE PROPHYLAXIS OF POSTOPERATIVE NAUSEA AND VOMITING IN HIGH-RISK SUBJECTS No dispute reported 06/30/2026 816789515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/17/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers No dispute reported 06/30/2026 793116063
Principal investigator 1 Endo Pharmaceuticals Inc. $10,000.00 12/14/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830763833
Principal investigator 1 Endo Pharmaceuticals Inc. $2,082.00 12/14/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830763845
Principal investigator 1 Siemens Medical Solutions USA, Inc. $18,226.00 12/10/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Not supplied No dispute reported 06/30/2026 768161726
Principal investigator 1 Innocoll Incorporated $650,412.00 11/26/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594429
Principal investigator 1 Innocoll Incorporated $2,352.00 11/26/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594431
Principal investigator 1 Endo Pharmaceuticals Inc. $569.00 11/16/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830763821
Principal investigator 1 Siemens Medical Solutions USA, Inc. $1,257.22 11/12/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768161358
Principal investigator 1 Siemens Medical Solutions USA, Inc. $1,460.00 11/05/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Not supplied No dispute reported 06/30/2026 768161502
Principal investigator 1 Eli Lilly and Company $2,250.00 11/01/2021 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A MULTIPLE-DOSE STUDY IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS,AND PHARMACODYNAMICS OF LY3502970 No dispute reported 06/30/2026 819459933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $780.00 10/29/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers No dispute reported 06/30/2026 793112889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,576.25 10/29/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 793112891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 10/29/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 793112893
Principal investigator 1 Vertex Pharmaceuticals Incorporated $247,202.60 10/29/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A Phase 2 randomized double blind placebo controlled study evaluating the efficacy and safety of VX-548 for acute pain after an abdominoplasty No dispute reported 06/30/2026 793094495
Principal investigator 1 Innocoll Incorporated $468,153.60 10/25/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594405
Principal investigator 1 Innocoll Incorporated $39,554.40 10/25/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594407
Principal investigator 1 Endo Pharmaceuticals Inc. $194.69 10/19/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830763799
Principal investigator 1 Endo Pharmaceuticals Inc. $219.00 10/19/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830763809
Principal investigator 1 Siemens Medical Solutions USA, Inc. $1,000.00 10/11/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768161394
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $324,665.55 10/08/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 793111607
Principal investigator 1 Siemens Medical Solutions USA, Inc. $314.08 10/08/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Not supplied No dispute reported 06/30/2026 768162974
Principal investigator 1 Endo Pharmaceuticals Inc. $6,008.00 09/28/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830763723
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $180,413.65 09/09/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy No dispute reported 06/30/2026 793096881
Principal investigator 1 Siemens Medical Solutions USA, Inc. $2,075.00 09/07/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Not supplied No dispute reported 06/30/2026 768161398
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $858.75 09/03/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 793109349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $82,415.00 08/27/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 793109105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38,200.00 08/27/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers No dispute reported 06/30/2026 793109107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,500.00 08/27/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers No dispute reported 06/30/2026 793109109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $167,853.60 08/27/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 793109111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,434.00 08/27/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers No dispute reported 06/30/2026 793109113
Principal investigator 1 Siemens Medical Solutions USA, Inc. $30,105.40 08/27/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768161020
Principal investigator 1 Siemens Medical Solutions USA, Inc. $13,478.30 08/27/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768161022
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $840.00 08/20/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers No dispute reported 06/30/2026 793108561
Principal investigator 1 Endo Pharmaceuticals Inc. $5,669.00 08/17/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830763785
Principal investigator 1 Innocoll Incorporated $361,629.60 07/29/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594347
Principal investigator 1 Innocoll Incorporated $7,000.00 07/29/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594349
Principal investigator 1 Innocoll Incorporated $7,500.00 07/29/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594351
Principal investigator 1 Innocoll Incorporated $7,000.00 07/29/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594353
Principal investigator 1 Innocoll Incorporated $7,500.00 07/29/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594355
Principal investigator 1 Innocoll Incorporated $139,472.40 07/29/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594357
Principal investigator 1 Innocoll Incorporated $182,838.00 07/29/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594359
Principal investigator 1 Heron Therapeutics, Inc. $1,200.00 07/22/2021 Non-covered Recipient Entity
ERG Holding Company
A Phase 4, Open-Label Study of Liposomal Bupivacaine Admixed With Bupivacaine HCl in Subjects Undergoing Total Knee Arthroplasty No dispute reported 06/30/2026 782091461
Principal investigator 1 Merck Sharp & Dohme Corporation $18,750.00 07/19/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V590 rVSV G-SARS-CoV-2-S, Live in Healthy Individuals 16 Years of Age or Older No dispute reported 06/30/2026 848761161
Principal investigator 1 Endo Pharmaceuticals Inc. $7,586.00 07/13/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830763775
Principal investigator 1 Siemens Medical Solutions USA, Inc. $20,579.85 07/12/2021 Non-covered Recipient Entity
ERG HOLDING
Not supplied No dispute reported 06/30/2026 768161138
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $833,133.60 06/25/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 793104981
Principal investigator 1 Endo Pharmaceuticals Inc. $1,800.00 06/15/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830763765
Principal investigator 1 Eli Lilly and Company $4,108.48 05/26/2021 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A MULTIPLE-DOSE STUDY IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS,AND PHARMACODYNAMICS OF LY3502970 No dispute reported 06/30/2026 819457563
Principal investigator 1 Endo Pharmaceuticals Inc. $3,500.00 05/18/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830763753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38,200.00 04/30/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 793101843
Principal investigator 1 Endo Pharmaceuticals Inc. $2,900.00 04/13/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830763743
Principal investigator 1 Siemens Medical Solutions USA, Inc. $46,561.40 03/12/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768160720
Principal investigator 1 Heron Therapeutics, Inc. $51,505.05 03/04/2021 Non-covered Recipient Entity
ERG Holding Company
A Phase 4, Open-Label Study of Liposomal Bupivacaine Admixed With Bupivacaine HCl in Subjects Undergoing Total Knee Arthroplasty No dispute reported 06/30/2026 782091457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70,907.00 02/26/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 793097469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $647,149.50 02/26/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS No dispute reported 06/30/2026 793097485
Principal investigator 1 Siemens Medical Solutions USA, Inc. $136,008.30 02/16/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768160718
Principal investigator 1 Siemens Medical Solutions USA, Inc. $22,500.00 02/16/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768160722
Principal investigator 1 Siemens Medical Solutions USA, Inc. $8,662.50 02/16/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768160724
Principal investigator 1 Endo Pharmaceuticals Inc. $7,000.00 01/19/2021 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830763733